Aclaris Therapeutis (ACRS) PT Raised to $15 at Cantor Fitzgerald; 'Data That Support Potential 1L, First-in-Class, Best-In-Class Drug for RA'
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen raised the price target on Aclaris Therapeutis (NASDAQ: ACRS) to $15.00 (from $7.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
